


2022 ICC recategorization facilitates risk stratification of myelodysplastic syndrome

January 19 2023, by Elana Gotkine



Clinical characteristics, outcomes, and genetic features vary among

different myelodysplastic syndrome (MDS) subtypes categorized using the 2022 International Consensus Classification (ICC), according to a study published online Jan. 1 in the *American Journal of Hematology*.

Wan-Hsuan Lee, from the National Taiwan University Hospital in Taipei, and colleagues examined the recategorization of myeloid neoplasms according to the ICC. MDS with blasts of 10 to 19 percent was classified as MDS/[acute myeloid leukemia](#) (AML); MDS with mutated *SF3B1*, irrespective of the number of ring sideroblasts, as MDS-*SF3B1*; and multi-hit *TP53* mutations as MDS with mutated *TP53* in the recategorization.

A total of 716 patients with MDS diagnosed according to the 2016 World Health Organization classification were recategorized. The researchers found that based on the ICC, 75.3 percent of patients remained in the MDS group, and after excluding 15 patients who were classified to the AML group, 24.7 percent were reclassified to the MDS/AML group. A distinct mutational landscape and poorer outcomes were seen for patients with MDS/AML versus those with MDS.

Patients with MDS-*SF3B1* had higher frequencies of *DNMT3A* and *TET2* mutations than those with MDS not otherwise specified, with single lineage or multilineage dysplasia. Dismal outcomes were seen for patients with mutated *TP53*, regardless of the blast percentage.

"The ICC ensures efficient segregation of this heterogeneous disease, with emphasis on the differences in molecular landscapes and prognoses among different disease subsets, which can help in accurate MDS diagnosis and effective risk-adapted treatment of [patients](#) with MDS," the authors write.

More information: Wan-Hsuan Lee et al, Clinico-genetic and prognostic analyses of 716 patients with primary myelodysplastic

syndrome and myelodysplastic syndrome/acute myeloid leukemia based on the 2022 International Consensus Classification, *American Journal of Hematology* (2023). [DOI: 10.1002/ajh.26799](https://doi.org/10.1002/ajh.26799)

Copyright © 2023 [HealthDay](#). All rights reserved.

Citation: 2022 ICC recategorization facilitates risk stratification of myelodysplastic syndrome (2023, January 19) retrieved 13 February 2024 from <https://medicalxpress.com/news/2023-01-icc-recategorization-stratification-myelodysplastic-syndrome.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.